Evidence map›Paper›PMID 32583355›Full record

ArticleEuropean journal of clinical pharmacology2020

Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension.

Stefan Momčilović, Andriana Jovanović, Danijela Radojković, Valentina N Nikolić, Slobodan M Janković, Milica Pešić, Jasmina R Milovanović

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stefan MomčilovićFaculty of Medicine, University of Niš, Blvd Zorana Djindjića 81, Niš, 18000, Serbia. m-stefan@mts.rs.ORCID http://orcid.org/0000-0002-6554-8160
Andriana JovanovićFaculty of Medicine, University of Niš, Blvd Zorana Djindjića 81, Niš, 18000, Serbia.
Danijela RadojkovićDepartment of Endocrinology, Faculty of Medicine, University of Niš, Niš, Serbia.
Valentina N NikolićDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Niš, Niš, Serbia.
Slobodan M JankovićDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Milica PešićDepartment of Endocrinology, Faculty of Medicine, University of Niš, Niš, Serbia.
Jasmina R MilovanovićDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
University of Nis · RSUniversity of Kragujevac · RS

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 175007Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja III41007
6 · The paper itself

Abstract

purposeGiven that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach.

methodsPopPK analysis was conducted using a nonlinear mixed effects model (NONMEM), version 7.3.0 (Icon Development Solutions). In our patients, a total daily dose of bisoprolol ranged from 1.25 to 10 mg. The drug was administrated orally as a single daily dose or in two divided doses per day.

resultsA wide range of the drug concentrations were noted (1-103 ng/mL) in the population consisted of the adult patients with type 2 diabetes mellitus. From a total of 21 separately assessed covariates, our results indicated that only creatinine clearance could have a potential impact on the variability of the clearance of bisoprolol.

conclusionRoutine assessment of renal function should be carried out before the initiation of treatment with bisoprolol in order to individualize the dose and to prevent possible accumulation and adverse drug reactions.

Indexed as

AdultAgedAged, 80 and overBisoprololCytochrome P-450 CYP3ADiabetes Mellitus, Type 2FemaleHumansHypertensionMaleMetabolic Clearance RateMiddle AgedBisoprololCYP3A4 protein, humanCytochrome P-450 CYP3ADiabetesDrug analysisHPLCPharmacokinetics

Identifiers

PMID32583355
OpenAlexW3037336730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.